Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma

Trial Profile

Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2019

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Renal cancer; Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jan 2019 Status changed from active, no longer recruiting to completed.
    • 20 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 Oct 2013 New source identified and integrated (M.D. Anderson Cancer Center, 2012-0694).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top